SANTA MONICA, Calif., April 22 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced the availability of an investor-focused corporate synopsis on its English language website, http://en.aidapharma.com, which may be downloaded as a pdf document. The synopsis details Aida Pharmaceuticals, Inc.'s public company financial information, current product line, the drugs in its development pipeline, as well as its future growth avenues.
About Aida Pharmaceuticals
Aida Pharmaceuticals, Inc. is a product-focused pharmaceuticals company
engaged in the formulation, clinical testing, registration, manufacture,
sales and marketing of advanced pharmaceutical and genetic products in
mainland China. The Company's mission is to discover, develop and market
meaningful new therapies that improve human health. Aida Pharmaceuticals,
Inc., in operation since March 1999, is headquartered in Hangzhou, the
People's Republic of China (the "PRC") with manufacturing, distribution and
sales points throughout mainland China. Aida Pharmaceuticals, Inc. is GMP
certified in the PRC and ISO9002 certified for quality assurance and
ISO14000 certified for ecologically-friendly practices.
(310) 450-9100 opt 1
Safe Harbor Statement Under The Private Securities Litigation Reform
Act of 1995: Except for historical information contained herein, the
statements in this news release are forward-looking statements that are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve known and
unknown risks and uncertainties, which may cause a company's actual
results, performance and achievement in the future to differ
|SOURCE Aida Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved